Supplementary Figure S5 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S5 shows additional analysis of the seribantumab efficacy in the LUAD-0061AS3 PDX model
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362411599
